In 2019, the proband consulted a geneticist at the Research center for medical genetics, who suggested the presumptive diagnosis of osteogenesis imperfecta type I. Molecular genetic testing using the massively parallel signature sequencing method that involved the analysis of the 17 genes currently associated with osteogenesis imperfecta (BMP1, COL1A1, COL1A2, CREB3L1, CRTAP, FKBP10, IFITM5, LEPRE1, PLOD2, PLS3, PPIB, SERPINF1, SERPINH1, SP7, SPARC, TMEM38B, WNT1) showed no pathogenic variants. This evidence concerns the gene PLOD2 and osteogenesis imperfecta.